Clinical Trial Update: A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF) [Phase 1]

View source ↗

Summary

Phase 1 trial updating safety, pharmacokinetics, and efficacy of OPC-108459 given as a single IV dose in patients with atrial fibrillation; study completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• OPC-108459 (OPC-108459)

Snippet

Sponsor: Otsuka Pharmaceutical Co., Ltd. | Conditions: Atrial Fibrillation | Phase 1 | Status: COMPLETED | Results posted: 2018-11-05